الولايات المتحدة · منصات وبيانات · MarketBeat

Kymera Therapeutics (NASDAQ:KYMR) Stock Price Target Raised at Morgan Stanley

نشره MarketBeat · الولايات المتحدة منذ 41 د

Morgan Stanley increased their price objective on Kymera Therapeutics from $135.00 to $146.00 and gave the stock an "overweight" rating in a research report on Tuesday.

اقرأ المقال كاملًا على MarketBeat سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (www.marketbeat.com)

يستحق القراءة أيضًا

The Motley Fool

Here's How Much a $10,000 Investment in Realty Income Will Get You in Monthly Dividends

MarketWatch

My wife cried when I found out she had only $80,000 in her 401(k). I have $2.2 million. Am I wrong to be shocked?

Benzinga

Kymera Therapeutics (NASDAQ:KYMR) Stock Price Target Raised at Morgan Stanley

مشاركة

يستحق القراءة أيضًا

Here's How Much a $10,000 Investment in Realty Income Will Get You in Monthly Dividends

My wife cried when I found out she had only $80,000 in her 401(k). I have $2.2 million. Am I wrong to be shocked?

Best Stocks Under $5

Novartis Raises Guidance After Trial Setbacks Hit Profit

Walmart copies a core Costco move that also benefits customers

ATOSS Software Q3 2026 Earnings Call Is Live